Supporting Information

Photoinduced borylation of *N*-tosylhydrazones and application into the drug derivation

Weijie Wang,^{‡[a]} Qingguang Zhang,^{‡[b]} Mengmeng Guo,^{‡[b]} Miaomiao Zhuo,^[b] Wei-Dong Zhang,^{*[a,b,c]} Qun Wang,^{*[b]} Yu Zhang^{*[b,d]}

^[a] School of Pharmacy, Ningxia Medical University, Yinchuan, Ningxia 750004, China

^[b]Shanghai Frontiers Science Center for Chinese Medicine Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, No. 1200, Cailun Road, Shanghai 201203, China

^[c] School of Pharmacy, Second Military Medical University, Shanghai 200433, China

^[d] School of Chemistry and Chemical Engineering; State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, NMPA Key Laboratory for Research and Evaluation of Innovative Drug, Henan Normal University, Xinxiang, Henan, 453007, China

*Corresponding author. E-mail address: yzhang@shutcm.edu.cn (Y. Zhang), wdzhangy@hotmail.com (W.-D. Zhang).

Table of Content

1. Materials and methods		
2. Setup for photochemical reactions	4	
3. Optimization details for the reaction conditions	5	
3.1 Control experiments ^{<i>a,b</i>}	5	
3.2 Screening of solvents ^{<i>a,b</i>}	5	
3.3 Screening of bases ^{<i>a,b</i>}	6	
3.4 Screening of <i>N</i> -tosylhydrazones ^{<i>a,b</i>}	6	
4. General procedures	7	
4.1 General procedure A to afford benzyl boronates	7	
4.2 General procedure B to afford <i>N</i> -tosylhydrazones	7	
4.3 General procedure C to afford 24-25	7	
5. The application of the reaction	9	
5.1 Gram-scale synthesis of 13d	9	
5.2 Gram-scale synthesis of 15d		
5.3 Gram-scale synthesis of 25d		
5.4 Further transformation of compound 25d		
6. Mechanistic investigations	14	
6.1 Time course		
6.2 On-off experiments	15	
6.3 Ultraviolet visible absorption experiments		
7. Characterization data of products and synthesized substrates	17	
8 NMR spectra of products and synthesized substrates	34	
9. References		

1. Materials and methods

Commercial reagents were used without purification. All solvents can be used directly without further drying and deoxygenation.

Organic solutions were concentrated under reduced pressure on a Büchi rotary evaporator using a water bath.

Kessil lamps were purchased from Tansoole, with precise wavelengths (390 nm).

Chromatographic purification of products was accomplished using flash column chromatography (FC) on silica gel (200-300 mesh).

Thin layer chromatography (TLC) was performed using MilliporeSigma glass TLC plates (silica gel 60 coated with F_{254} , 250 μ m) and spots were visualized using UV light (254 nm).

NMR-spectra were recorded on Bruker DRX-500 (500 MHz) spectrometer and calibrated by using residual undeuterated chloroform (δ = 7.26 ppm for ¹H, 77.16 ppm for ¹³C) and DMSO (δ = 2.50 ppm for ¹H, 39.52 ppm for ¹³C) as internal references. The following abbreviations were used to describe peak splitting patterns when appropriate: s = singlet, d = doublet, t = triplet, q = quartet, dd = doublet of doublets, m = multiplet, td = triplet of doublets, ddd = doublet of doublets.

High-resolution mass spectra (HRMS) were recorded on an Agilent MSD-Trap-XCT or Q-Tof micro mass spectrometer.

Ultraviolet-visible absorption experiments were performed using a UV-8000S(T) spectrophotometer.

Cell viability assay

The RKO cell lines were plated into 96-well plates $(1 \times 104 \text{ cells/ml})$ containing different concentrations of **24d**, **25d**, **25e**, **25f**, **25g** and **25h**. After treatment for 24 h, the effect of these compounds on cell viability was measured via a Cell Counting Kit-8 (Yeasen, Shanghai, China) according to the manufacturer's instructions.

2. Setup for photochemical reactions

The reaction setup is depicted in **Figure S1**. The reaction setup consists of 4 commercially available Kessil lamps which were purchased from Tansoole, with precise wavelengths (390 nm), cooling of the setup was performed by two commercially available fans to keep the temperature around 30 °C. The distance between the lamp and the schlenk tube was set 3 cm. Magnetic stirring was performed at 500 rpm.



Figure S1. Photochemical set-up for regular-scale reactions.



Figure S2. Photochemical set-up for large-scale reactions.

3. Optimization details for the reaction conditions

3.1 Control experiments^{*a,b*}

Table S1:



^aStandard conditions: **13a** (0.2 mmol, 1.0 equiv.), **1b** (0.3 mmol, 1.5 equiv.), KO'Bu (0.4 mmol, 2.0 equiv.), MeOH (0.6 mmol, 3.0 equiv.), toluene (1 mL), irradiation with 40 W Kessil lamps (390 nm) at room temperature (around 30 °C) with cooling fan under air for 6 h. ^{*b*}Yields were determined by ¹H NMR analysis using dibromomethane as an internal standard.

3.2 Screening of solvents^{*a,b*}

Br	B ₂ pin ₂	KO ^f Bu (2.0 equiv.) MeOH (3.0 equiv.) Solvent (1.0 mL), Ar, 6 h Kessil lamp 390 nm, 40 W	Br O
13a	1b		13d
Entry		Solvent (0.2 M)	Yield [%] ^b
1		1,4-Dioxane	trace
2		DCM	16
3		DCE	trace
4		MeCN	n.d.
5		2-Me-THF	n.d.

Table S2:

^{*a*}Reaction conditions: **13a** (0.2 mmol, 1.0 equiv.), **1b** (0.3 mmol, 1.5 equiv.), KO'Bu (0.4 mmol, 2.0 equiv.), MeOH (0.6 mmol, 3.0 equiv.), solvent, irradiation with 40 W Kessil lamps (390 nm) at room temperature (around 30 °C) with cooling fan under air for 6 h. ^{*b*}Yields were determined by ¹H NMR analysis using dibromomethane as an internal standard.

3.3 Screening of bases^{*a,b*}

Table S3:

Br	+ B ₂ pin ₂	Base MeOH (3.0 equiv.) toluene (1.0 mL), Ar, 6 h Kessil lamp 390 nm, 40 W	Br O
13a	1b		13d
Entry		Base	Yield [%] ^b
1		KO'Bu (2.0 equiv.)	83
2		DBU (2.0 equiv.)	n.d.
3		K ₂ CO ₃ (2.0 equiv.)	trace
4		Cs ₂ CO ₃ (2.0 equiv.)	30
5		NaOMe (2.0 equiv.)	52

^{*a*}Standard conditions: **13a** (0.2 mmol, 1.0 equiv.), **1b** (0.3 mmol, 1.5 equiv.), base, MeOH (0.6 mmol, 3.0 equiv.), toluene (1 mL), irradiation with 40 W Kessil lamps (390 nm) at room temperature (around 30 $^{\circ}$ C) with cooling fan under air for 6 h. ^{*b*}Yields were determined by ¹H NMR analysis using dibromomethane as an internal standard.

3.4 Screening of *N*-tosylhydrazones ^{*a,b*}

$\begin{matrix} NNHTs \\ \downarrow & + & B_2pin_2 \end{matrix}$	KOtBu (2.0 equiv.) MeOH (3.0 equiv.) toluene (1.0 mL), Ar, 6 h	
$R_1 \sim R_2$	Kessil lamp 390 nm, 40 W	\dot{R}_2 \dot{O}
13a' 1b		13d'
Entry	Reagent 1	Yield [%] ^b
1	13ab	55
2	13ac	n.d.
3	13ad	trace
4	13ae	trace

Table S4:

^{*a*}Standard conditions: **13a'** (0.2 mmol, 1.0 equiv.), **1b** (0.3 mmol, 1.5 equiv.), KO'Bu (0.4 mmol, 2.0 equiv.), MeOH (0.6 mmol, 3.0 equiv.), toluene (1 mL), irradiation with 40 W Kessil lamps (390 nm) at room temperature (around 30 °C) with cooling fan under air for 6 h. ^{*b*}Yields were determined by ¹H NMR analysis using 1,3,5-trimethoxybenzene as an internal standard.



4. General procedures

4.1 General procedure A to afford benzyl boronates



A 5 mL Schlenk tube containing a stirring bar was charged with 0.2 mmol of *N*-tosylhydrazone, B_2pin_2 (1.5 equiv., 0.3 mmol, 76.2 mg), KO'Bu (2.0 equiv., 0.4 mmol, 44.9 mg), MeOH (3.0 equiv., 0.6 mmol, 23.6 µL), toluene (1 mL) was added. The reaction was kept for 6 h under 390 nm Kessil lamp reaction setup (the progress can be monitored *via* TLC). Then, the resulting mixture underwent an aqueous workup and was extracted three times with ethyl acetate. The combined organic layers were dried over anhydrous Na₂SO₄ and concentrated *in vacuo*. Products were purified by column chromatography with ethyl acetate and hexane as solvents.

4.2 General procedure B to afford N-tosylhydrazones

$$\begin{array}{c} O \\ R_1 \\ H \end{array} + TSNHNH_2 \\ \hline MeOH \\ MeOH \\ R_1 \\ H \end{array} + NNHTS$$

N-tosylhydrazones were prepared according a reported procedure.¹ To a stirred solution of tosylhydrazide (10 mmol) in MeOH (10 mL) at room temperature, aldehyde (1.0 equiv.) was added dropwise (or portionwise if solid). The reaction was completed within 0.1-3 h. After that, the solvent was removed directly under reduced pressure, and further purified by recrystallization or *via* silica gel chromatography (hexane:EtOAc, 2:1).¹

4.3 General procedure C to afford 24-25

To a 0°C solution of 4-hydroxybenzaldehyde (1.78 g, 14.5 mmol) in dichloromethane (30 mL) Ibuprofen (3.0 g, 2.9 mL, 14.5 mmol) was added followed by DCC (3.6 g, 17.4 mmol) and DMAP (0.18 g, 1.45 mmol), purging the flask for three times under vacuum and three times argon, Then, the homogeneous solution was removed from the ice bath and stirred at room temperature for 12 h. The reaction mixture was saturated aqueous NaCl (2x) and finally with brine. The combined organic layers were dried over

 $MgSO_4$, filtered, and concentrated under reduced pressure to obtain the product as a clear oil (3.6 g.11.6 mmol, 81%).²

5. The application of the reaction

5.1 Gram-scale synthesis of 13d

Synthesis of 13d in gram scale:



Following the general procedure A, to a glass vial, containing the **13a** (1.76 g, 5.0 mmol), **1b** (1.91 g, 7.5 mmol, 1.5 equiv.), KO'Bu (1.12 g, 10.0 mmol, 2.0 equiv.), MeOH (480.6 mg, 15.0 mmol, 3.0 equiv.) was added toluene (25 mL). The vial was placed in the 390 nm irradiation setup as shown on **Figure S2**. The reaction was stirred for 10 h (the progress can be monitored *via* TLC), then the solvent was evaporated, the resulting mixture underwent an aqueous workup and was extracted three times with ethyl acetate. The combined organic layers were dried over anhydrous Na₂SO₄ and concentrated *in vacuo*. Purification by column chromatography on silica gel with petroleum ether and ethyl acetate (v/v = 60/1) as solvents afforded product **13d** as a yellow solid (1.01 g, 68% yield).

5.2 Gram-scale synthesis of 15d

Synthesis of 15d in gram scale:



Following the general procedure A, to a glass vial, containing the **15a** (3.00 g, 8.5 mmol), **1b** (3.24 g, 12.75 mmol, 1.5 equiv.), KO'Bu (1.91 g, 17.0 mmol, 2.0 equiv.), MeOH (817.02 mg, 25.5 mmol, 3.0 equi) was added toluene (43 mL). The vial was placed in the 390 nm irradiation setup as shown on **Figure S2**. The reaction was stirred for 10 h (the progress can be monitored *via* TLC), then the solvent was evaporated, the resulting mixture underwent an aqueous workup and was extracted three times with ethyl acetate. The combined organic layers were dried over anhydrous Na₂SO₄ and concentrated *in vacuo*. Purification by column chromatography on silica gel with petroleum ether and ethyl acetate (v/v = 60/1) as solvents afforded product **15d** as a yellow oli (1.48 g, 59% yield).

5.3 Gram-scale synthesis of 25d

Synthesis of 25d in gram scale:



Following the general procedure A, to a glass vial, containing the **25a** (2.61 g, 5.0 mmol), **1b** (1.91 g, 7.5 mmol, 1.5 equiv.), KO'Bu (1.12 g, 10.0 mmol, 2 equiv.), MeOH (480.6 mg, 15.0 mmol, 3.0 equiv.) was added toluene (25 mL). The vial was placed in the 390 nm irradiation setup as shown on **Figure S2**. The reaction was stirred for 10 h (the progress can be monitored *via* TLC), then the solvent was evaporated, the resulting mixture underwent an aqueous workup and was extracted three times with ethyl acetate. The combined organic layers were dried over anhydrous Na₂SO₄ and concentrated *in vacuo*. Purification by column chromatography on silica gel with petroleum ether and ethyl acetate (v/v = 30/1) as solvents afforded product **25d** as a white oil (1.30 g, 56% yield).

5.4 Further transformation of compound 25d



Procedure D: The title compound was prepared following a literature protocol.³ To a stirred solution of **25d** (46.6 mg, 0.1 mmol) in DMSO (1.0 mL), was added N-nitrosomorpholine. and (23.0 mg, 0.2 mmol, 2.0 equiv). At Ar atmosphere, the mixture was stirred at room temperature for 12 hours. (the progress can be monitored *via* TLC). Then, place the reaction quench with water (2 mL) and extract with ethyl acetate (3 x 15 mL). Filter the mixture and concentrate the solvent. Products were purified *via* column chromatography with petroleum ether/ethyl acetate (10/1, v/v) as solvents, to obtain **25e** (31.4 mg, 85%) as a colorless oil.



Procedure E: The title compound was prepared following a literature protocol.⁴ To a stirred solution of **25d** (233 mg, 0.5 mmol) in Et₂O (1.0 mL), was added (+)-pinanediol (110.65 mg, 0.65 mmol, 1.3 equiv). The mixture was stirred at room temperature for 24 hours. (the progress can be monitored *via* TLC). Then, place the reaction quench with water (2 mL) and extract with ethyl acetate (3 x 15 mL). Filter the mixture and concentrate the solvent. Products were purified *via* column chromatography with petroleum ether/ethyl acetate (30/1, v/v) as solvents, to obtain **25f** (228 mg, 88%) as a colorless oil.



Procedure F: The title compound was prepared following a literature protocol.⁵ A mixture of benzyl pinacol boronic acid ester **25d** (58.3 mg, 0.125 mmol), *N*-methylaniline (14.7 mg, 0.138 mmol), di-tertbutyl peroxide (36.6 mg, 0.25 mmol), Cu(OAc)₂ (1.1 mg, 6.3 µmol), and toluene (0.50 mL) was stirred at 50 °C for 24 h in a sealed tube. Then, the solvent was removed in vacuo and the product was isolated by column chromatography on silica gel (petroleum ether/ethyl acetate = 10/1) to give *N*-benzyl-*N*-methylaniline **25g** (35.8 mg, 63% yield).



Procedure G: The title compound was prepared following a literature protocol.⁵ A mixture of benzyl pinacol boronic acid ester **25d** (116.6 mg, 0. 25 mmol), 4-bromophenol (47.6 mg, 0.275 mmol), di-tertbutyl peroxide (73.2 mg, 0.5 mmol), Cu(OAc)₂ (2.2 mg, 12.6 μ mol), and toluene (1.0 mL) was stirred at 50 °C for 24 h in a sealed tube. Then, the solvent was removed in vacuo and the product was isolated by column chromatography on silica gel (petroleum ether/ethyl acetate = 10/1) to give *N*-benzyl-*N*-methylaniline **25h** (63.8 mg, 50% yield).

6. Mechanistic investigations

6.1 Time course



N-tosylhydrazone **13a** (0.4 mmol, 140.8 mg), **1b** (152.4 mg, 0.6 mmol, 1.5 equiv.), KO'Bu (89.8 mg, 0.4 mmol, 2.0 equiv.), MeOH (480.6 mg, 15.0 mmol, 3.0 equiv.), and internal standard (1,3,5-trimethoxybenzene, 0.1 mmol, 16.8 mg) were added into a dry 10 mL Schlenk tube equipped with a stirring bar, followed by the addition of toluene (2 mL). Then the reaction mixture was irradiated by a 390 nm Kessil lamps (40 W) at room temperature. An aliquot of the reaction mixture then taken at the indicated times and the yields were determined by ¹H NMR spectroscopy.



Figure S3. Time course experiment, yield was determined by ¹H NMR with 1,3,5-trimethoxybenzene as the internal standard.



A dry 10 mL Schlenk tube containing a stirring bar was charged with *N*-tosylhydrazone **13a** (0.4 mmol, 140.8 mg), **1b** (152.4 mg, 0.6 mmol, 1.5 equiv.), KO'Bu (89.8 mg, 0.4 mmol, 2 equiv.), MeOH (480.6 mg, 15.0 mmol, 3.0 equiv.), and 1,3,5-trimethoxybenzene (0.2 mmol, as the internal standard). After purging the flask three times under vacuum and three times under argon, it was charged with 2.0 mL of toluene. Then the mixture was irradiated by 40 W 390 nm Kessil lamps reaction setup at room temperature. After 1 h, the Kessil lamps were turned off, and 0.2 ml of reaction solvent was taken for NMR analysis. Then the tube was reacted in the absence of light for an additional 1 h, and 0.2 ml of reaction solvent was removed for analysis, and the Kessil lamps were turned back on to irradiate the analyzed mixtures. So repeatedly, the yields were determined by ¹H NMR spectroscopy.



Figure S4. The comparison of On-off experiment yields determined by hydrogen spectrometry.

6.3 Ultraviolet visible absorption experiments

Ultraviolet-visible absorption experiments were performed using a UV-8000S(T) spectrophotometer. In each experiment, the varying samples were combined in the solvent toluene in screw-top 1.0 cm quartz cuvettes.



Figure S5. UV/vis absorption spectra of individual reaction components and a combination thereof. Ultravioletvisible absorption experiments: **13a** (2.0×10^{-4} M) in toluene, [**13a** + KO'Bu] (2.0×10^{-4} M) in toluene. The right picture is a partial enlargement of the left picture.

7. Characterization data of products and synthesized substrates.



N'-benzylidene-4-methylbenzenesulfonohydrazide (1a): Following the general procedure B, it was obtained as a white solid by recrystallization (isolated yield: 86%). 1a was known in the published literature.⁶

¹**H** NMR (500 MHz, CDCl₃) δ 8.61 (s, 1H), 7.90 (d, J = 8.3 Hz, 2H), 7.81 (s, 1H), 7.59 – 7.52 (m, 2H), 7.37 – 7.27 (m, 5H), 2.38 (s, 3H).

HRMS (ESI-TOF) m/z: $[M + H]^+$ calcd. for $C_{14}H_{14}N_2O_2SH$: 275.0849, found: 275.0873.



4-methyl-*N***'-(4-methylbenzylidene)benzenesulfonohydrazide (2a)**: Following the general procedure B, it was obtained as a white solid by recrystallization (isolated yield: 75%). **2a** was known in the published literature.⁷

¹**H NMR** (500 MHz, DMSO-*d*₆) δ 11.35 (s, 1H), 7.86 (s, 1H), 7.75 (d, *J* = 8.4 Hz, 2H), 7.41 (dd, *J* = 18.8, 8.2 Hz, 4H), 7.19 (d, *J* = 8.0 Hz, 2H), 2.34 (s, 3H), 2.28 (s, 3H).

HRMS (ESI-TOF) m/z: $[M + H]^+$ calcd. for $C_{15}H_{16}N_2O_2SH$: 289.1005, found: 289.0089.



N'-(4-(tert-butyl)benzylidene)-4-methylbenzenesulfonohydrazide (3a): Following the general procedure B, it was obtained as a white solid by recrystallization (isolated yield: 72%). 3a was known in the published literature.⁸

¹**H NMR** (500 MHz, DMSO-*d*₆) δ 11.34 (s, 1H), 7.87 (s, 1H), 7.75 (d, *J* = 8.3 Hz, 2H), 7.47 (d, *J* = 8.5 Hz, 2H), 7.40 (dd, *J* = 8.1, 3.0 Hz, 4H), 2.35 (s, 3H), 1.25 (s, 9H).

HRMS (ESI-TOF) m/z: $[M + H]^+$ Calcd for $C_{18}H_{22}N_2O_2SH$ 331.1475; Found 331.1490.



N'-(4-methoxybenzylidene)-4-methylbenzenesulfonohydrazide (4a): Following the general procedure B, it was obtained as a white solid by recrystallization (isolated yield: 88%). 4a was known in the published literature.⁹

¹**H NMR** (500 MHz, DMSO- d_6) δ 11.24 (s, 1H), 7.84 (s, 1H), 7.75 (d, J = 8.3 Hz, 2H), 7.49 (d, J = 8.8 Hz, 2H), 7.43 – 7.37 (m, 2H), 6.94 (d, J = 8.8 Hz, 2H), 3.76 (s, 3H), 2.35 (s, 3H).

HRMS (ESI-TOF) m/z: $[M + H]^+$ Calcd for $C_{15}H_{16}N_2O_3SH$ 305.0954; Found 305.0980.



4-methyl-*N***'-(4-(methylthio)benzylidene)benzenesulfonohydrazide (5a):** Following the general procedure B, it was obtained as a white solid by recrystallization (isolated yield: 94%). **5a** was known in the published literature.¹⁰

¹**H NMR** (500 MHz, DMSO- d_6) δ 11.39 (s, 1H), 7.86 (s, 1H), 7.76 (d, J = 8.3 Hz, 2H), 7.48 (d, J = 8.5 Hz, 2H), 7.39 (d, J = 7.8 Hz, 2H), 7.24 (d, J = 8.5 Hz, 2H), 2.46 (s, 3H), 2.34 (s, 3H).

HRMS (ESI-TOF) m/z: $[M + H]^+$ Calcd for $C_{15}H_{16}N_2O_2S_2H$ 321.0726; Found 321.0745.



4-methyl-*N***'-(4-phenoxybenzylidene)benzenesulfonohydrazide (6a):** Following the general procedure B, it was obtained as a white solid by recrystallization (isolated yield: 82%). **6a** was known in the published literature.¹⁰

¹**H NMR** (500 MHz, DMSO- d_6) δ 11.38 (s, 1H), 7.89 (s, 1H), 7.76 (d, J = 8.3 Hz, 2H), 7.56 (d, J = 8.7 Hz, 2H), 7.44 – 7.36 (m, 4H), 7.18 (t, J = 7.4 Hz, 1H), 7.04 (d, J = 7.6 Hz, 2H), 6.98 (d, J = 8.4 Hz, 2H), 2.35 (s, 3H).

HRMS (ESI-TOF) m/z: $[M + H]^+$ Calcd for $C_{20}H_{18}N_2O_3SH$ 367.1111; Found 367.1132.



N'-([1,1'-biphenyl]-4-ylmethylene)-4-methylbenzenesulfonohydrazide (7a): Following the general procedure B, it was obtained as a white solid by recrystallization (isolated yield: 86%). 7a was known in the published literature.¹¹

¹**H NMR** (500 MHz, DMSO-*d*₆) δ 11.50 (s, 1H), 7.95 (s, 1H), 7.78 (d, *J* = 8.0 Hz, 2H), 7.70 (d, *J* = 8.3 Hz, 2H), 7.69 – 7.66 (m, 2H), 7.64 (d, *J* = 8.3 Hz, 2H), 7.46 (t, *J* = 7.6 Hz, 2H), 7.41 (d, *J* = 8.1 Hz, 2H), 7.40 – 7.35 (m, 1H), 2.35 (s, 3H).

HRMS (ESI-TOF) m/z: $[M + Na]^+$ Calcd for $C_{20}H_{18}N_2O_2SNa$ 373.0981; Found 373.0998



N'-(4-ethynylbenzylidene)-4-methylbenzenesulfonohydrazide (8a): Following the general procedure B, it was obtained as a white solid by recrystallization (isolated yield: 88%).

¹**H NMR** (500 MHz, DMSO- d_6) δ 11.58 (s, 1H), 7.90 (s, 1H), 7.76 (d, J = 8.3 Hz, 2H), 7.56 (d, J = 8.4 Hz, 2H), 7.48 (d, J = 8.3 Hz, 2H), 7.44 – 7.33 (m, 2H), 4.33 (s, 1H), 2.36 (s, 3H).

¹³**C NMR** (126 MHz, DMSO-*d*₆) δ 145.9, 143.5, 136.1, 134.0, 132.1, 129.7, 127.2, 126.9, 123.0, 83.1, 82.6, 21.0.

HRMS (ESI-TOF) m/z: $[M + H]^+$ Calcd for $C_{16}H_{14}N_2O_2SNa$ 321.0668; Found 321.0687.



4-methyl-N'-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-

yl)benzylidene)benzenesulfonohydrazide (9a): Following the general procedure B, it was obtained as a white solid by recrystallization (isolated yield: 90%).

¹**H NMR** (500 MHz, DMSO- d_6) δ 11.56 (s, 1H), 7.91 (s, 1H), 7.75 (d, J = 8.3 Hz, 2H), 7.67 (d, J = 8.2Hz, 2H), 7.56 (d, J = 8.1 Hz, 2H), 7.43 – 7.34 (m, 2H), 2.35 (s, 3H), 1.28 (s, 12H).

¹³C NMR (126 MHz, DMSO-*d*₆) δ 146.6, 143.5, 136.3, 136.1, 134.8, 129.7, 127.2, 126.1, 83.8, 24.7, 21.0

HRMS (ESI-TOF) m/z: $[M + H]^+$ Calcd for $C_{20}H_{25}BN_2O_4SH$ 401.1701; Found 401.1732.



4-methyl-N'-(4-(trifluoromethoxy)benzylidene)benzenesulfonohydrazide (10a): Following the general procedure B, it was obtained as a white solid by recrystallization (isolated yield: 88%). 10a was known in the published literature.¹³

¹**H NMR** (500 MHz, CDCl₃) δ 8.10 (s, 1H), 7.87 (d, J = 8.3 Hz, 2H), 7.75 (s, 1H), 7.60 (d, J = 8.7 Hz, 2H), 7.32 (d, J = 8.1 Hz, 2H), 7.25 – 7.11 (m, 2H), 2.41 (s, 3H).

HRMS (ESI-TOF) m/z: $[M + Na]^+$ Calcd for $C_{15}H_{13}F_3N_2O_3SNa 381.0491$; Found 381.0513.



N'-(4-fluorobenzylidene)-4-methylbenzenesulfonohydrazide (11a): Following the general procedure B, it was obtained as a white solid by recrystallization (isolated yield: 86%).

¹**H NMR** (500 MHz, DMSO- d_6) δ 11.48 (s, 1H), 7.92 (s, 1H), 7.83 – 7.76 (m, 2H), 7.61 (dd, J = 8.7,

5.7 Hz, 2H), 7.39 (d, J = 8.1 Hz, 2H), 7.21 (t, J = 8.8 Hz, 2H), 2.33 (s, 3H).

¹³C NMR (126 MHz, DMSO- d_6) δ 164.1, 162.1, 145.9, 143.5, 136.1, 130.3 (d, J_{C-F} = 1.26 Hz), 129.7, 128.9 (d, J_{C-F} = 8.82 Hz), 127.3, 115.9 (d, J_{C-F} = 22.68 Hz), 21.0.

HRMS (ESI-TOF) m/z: $[M + Na]^+$ Calcd for $C_{14}H_{13}N_2O_2SNa$ 315.0574; Found 315.0599.



N'-(4-chlorobenzylidene)-4-methylbenzenesulfonohydrazide (12a): Following the general procedure B, it was obtained as a white solid by recrystallization (isolated yield: 93%). 12a was known in the published literature.14

¹**H NMR** (500 MHz, DMSO- d_6) δ 11.56 (s, 1H), 7.90 (s, 1H), 7.77 (d, J = 8.3 Hz, 2H), 7.58 (d, J = 8.5Hz, 2H), 7.45 (d, J = 8.5 Hz, 2H), 7.40 (d, J = 8.2 Hz, 2H), 2.34 (s, 3H).

HRMS (ESI-TOF) m/z: $[M + H]^+$ Calcd for $C_{14}H_{14}ClN_2O_2SH$ 309.0459; Found 309.0476.



N'-(4-bromobenzylidene)-4-methylbenzenesulfonohydrazide (13a): Following the general procedure B, it was obtained as a white solid by recrystallization (isolated yield: 89%). 13a was known in the published literature.¹⁴

¹**H NMR** (500 MHz, DMSO-*d*₆) δ 11.56 (s, 1H), 7.89 (s, 1H), 7.79 – 7.73 (m, 2H), 7.61 – 7.56 (m, 2H), 7.52 – 7.48 (m, 2H), 7.43 – 7.36 (m, 2H), 2.35 (s, 3H).

HRMS (ESI-TOF) m/z: $[M + H]^+$ Calcd for $C_{14}H_{13}BrN_2O_2SH$ 352.9954; Found 352.9968.



N'-(3-fluorobenzylidene)-4-methylbenzenesulfonohydrazide (14a): Following the general procedure B, it was obtained as a white solid by recrystallization (isolated yield: 90%). 14a was known in the published literature.¹³

¹**H NMR** (500 MHz, DMSO-*d*₆) δ 11.60 (s, 1H), 7.90 (s, 1H), 7.76 (d, J = 8.3 Hz, 2H), 7.44 – 7.39 (m, 4H), 7.35 (m, 1H), 7.23 (m, 1H), 2.36 (s, 3H).

HRMS (ESI-TOF) m/z: $[M + H]^+$ Calcd for $C_{14}H_{13}FN_2O_2SH$ 293.0755; Found 293.0784.



N'-(**3-bromobenzylidene**)-**4-methylbenzenesulfonohydrazide** (**15a**): Following the general procedure B, it was obtained as a white solid by recrystallization (isolated yield: 90%).

¹**H NMR** (500 MHz, DMSO- d_6) δ 11.66 (s, 1H), 7.89 (s, 1H), 7.77 (d, J = 8.3 Hz, 2H), 7.72 (s, 1H), 7.58 – 7.52 (m, 2H), 7.39 (d, J = 8.1 Hz, 2H), 7.33 (t, J = 7.9 Hz, 1H), 2.33 (s, 3H).

¹³C NMR (126 MHz, DMSO-*d*₆) *δ* 145.2, 143.6, 136.1, 132.6, 130.9, 129.7, 129.1, 127.2, 125.7, 122.1, 21.0.

HRMS (ESI-TOF) m/z: $[M + H]^+$ Calcd for $C_{14}H_{13}BrN_2O_2SH$ 352.9954; Found 352.9971.



4-methyl-*N***'-(3-(trifluoromethyl)benzylidene)benzenesulfonohydrazide** (16a): Following the general procedure B, it was obtained as a white solid by recrystallization (isolated yield: 93%). 16a was known in the published literature.¹³

¹**H NMR** (500 MHz, CDCl₃) δ 8.14 (s, 1H), 7.88 (d, J = 8.3 Hz, 2H), 7.82 – 7.74 (m, 3H), 7.65 – 7.58 (m, 1H), 7.49 (t, J = 7.8 Hz, 1H), 7.33 (d, J = 8.1 Hz, 2H), 2.42 (s, 3H).

HRMS (ESI-TOF) m/z: $[M + Na]^+$ Calcd for $C_{15}H_{12}F_3N_2O_2SNa$ 365.0542; Found 365.0566.



4-methyl-*N***'-(naphthalen-2-ylmethylene)benzenesulfonohydrazide** (17a): Following the general procedure B, it was obtained as a white solid by recrystallization (isolated yield: 92%). **17a** was known in the published literature.¹⁴

¹**H NMR** (500 MHz, DMSO-*d*₆) δ 11.56 (s, 1H), 8.57 (d, *J* = 8.3 Hz, 1H), 8.50 (s, 1H), 7.97 (d, *J* = 8.0 Hz, 2H), 7.83 (d, *J* = 8.3 Hz, 2H), 7.71 (d, *J* = 6.0 Hz, 1H), 7.62 – 7.50 (m, 3H), 7.43 (d, *J* = 8.2 Hz, 2H), 2.34 (s, 3H).

HRMS (ESI-TOF) m/z: $[M + H]^+$ Calcd for $C_{18}H_{16}N_2O_2SH$ 325.1005; Found: 325.1021.



N'-(2-bromo-4-methoxybenzylidene)-4-methylbenzenesulfonohydrazide (18a): Following the general procedure B, it was obtained as a white solid by recrystallization (isolated yield: 73%). 18a was known in the published literature.¹⁴

¹**H NMR** (500 MHz, DMSO- d_6) δ 11.55 (s, 1H), 8.15 (s, 1H), 7.76 (d, J = 8.3 Hz, 2H), 7.66 (d, J = 8.8 Hz, 1H), 7.39 (d, J = 7.9 Hz, 2H), 7.17 (d, J = 2.6 Hz, 1H), 6.98 (dd, J = 8.8, 2.5 Hz, 1H), 3.77 (s, 3H), 2.34 (s, 3H).

¹³C NMR (126 MHz, DMSO-*d*₆) δ 161.6, 145.5, 144.0, 136.5, 130.2, 128.2, 127.7, 125.3, 124.5, 117.9, 115.5, 56.3, 21.5.

HRMS (ESI-TOF) m/z: $[M + H]^+$ Calcd for $C_{15}H_{15}BrN_2O_3SH$ 383.0060; Found: 383.0042.



N'-(3,5-dichlorobenzylidene)-4-methylbenzenesulfonohydrazide (19a): Following the general procedure B, it was obtained as a white solid by recrystallization (isolated yield: 80%).

¹**H NMR** (500 MHz, DMSO-*d*₆) δ 11.82 (s, 1H), 7.87 (s, 1H), 7.77 (d, *J* = 8.3 Hz, 2H), 7.60 (t, *J* = 1.9 Hz, 1H), 7.57 (d, *J* = 2.0 Hz, 2H), 7.44 - 7.38 (m, 2H), 2.35 (s, 3H).

¹³C NMR (126 MHz, DMSO-*d*₆) δ 143.7, 143.7, 137.3, 136.0, 134.6, 129.8, 129.1, 127.2, 125.0, 21.0. HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₁₄H₁₂Cl₂N₂O₂SH 343.0069; Found 343.0083.



4-methyl-*N***'-(2,4,6-trifluorobenzylidene)benzenesulfonohydrazide** (**20a**): Following the general procedure B, it was obtained as a white solid by recrystallization (isolated yield: 66%). **21a** was known in the published literature.¹⁴

¹**H NMR** (500 MHz, DMSO-*d*₆) δ 11.72 (s, 1H), 7.91 (s, 1H), 7.74 (d, J = 8.3 Hz, 2H), 7.41 (d, J = 8.1 Hz, 2H), 7.25 (t, J = 9.1 Hz, 2H), 2.36 (s, 3H).

HRMS (ESI-TOF) m/z: $[M + H]^+$ Calcd for $C_{14}H_{11}F_3N_2O_2SH$ 329.0566; Found: 329.0581.



N'-((4-bromothiophen-3-yl)methylene)-4-methylbenzenesulfonohydrazide (21a): Following the general procedure B, it was obtained as a white solid by recrystallization (isolated yield: 74%). ¹H NMR (500 MHz, DMSO- d_6) δ 11.54 (s, 1H), 7.90 (d, *J* = 2.9 Hz, 2H), 7.80 – 7.72 (m, 3H), 7.39 (d, *J* = 8.1 Hz, 2H), 2.34 (s, 3H).

¹³C NMR (126 MHz, DMSO-*d*₆) δ 143.6, 140.7, 136.1, 133.3, 129.7, 127.3, 126.2, 125.6, 109.6, 21.0. HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₁₂H₁₁BrN₂O₂S₂H 358.9518; Found: 358.9531.



N', N''-1,3-phenylenebis(methanylylidene))bis(4-methylbenzenesulfonohydrazide) (22a): Following the general procedure B, it was obtained as a white solid by recrystallization (isolated yield: 88%).

¹**H NMR** (500 MHz, DMSO-*d*₆) δ 11.55 (s, 2H), 7.92 (s, 2H), 7.77 (d, *J* = 8.3 Hz, 4H), 7.74 (d, *J* = 1.7 Hz, 1H), 7.55 (dd, *J* = 7.7, 1.7 Hz, 2H), 7.39 (d, *J* = 8.0 Hz, 5H), 2.34 (s, 6H).

¹³C NMR (126 MHz, DMSO-*d*₆) δ 146.3, 143.5, 136.1, 134.2, 129.7, 129.3, 128.3, 127.2, 124.5, 21.0. HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₂₂H₂₂N₄O₄S₂H 471.1115; Found 471.1134.



N', *N'''*-**1,4-phenylenebis(methanylylidene))bis(4-methylbenzenesulfonohydrazide) (23a):** Following the general procedure B, it was obtained as a white solid by recrystallization (isolated yield: 93%). **23a** was known in the published literature.¹⁵

¹**H NMR** (500 MHz, DMSO-*d*₆) δ 11.54 (s, 2H), 7.88 (s, 2H), 7.80 – 7.69 (m, 4H), 7.56 (s, 4H), 7.40 (d, J = 8.1 Hz, 4H), 2.35 (s, 6H).

HRMS (ESI-TOF) m/z: $[M + H]^+$ Calcd for $C_{22}H_{22}N_4O_4S_2H$ 471.1115; Found 471.1129.



4-((2-tosylhydrazono)methyl)phenyl 2-(4-isobutylphenyl)propanoate (24a): Following the general procedure B, it was obtained as a white solid by recrystallization (isolated yield: 65%).

¹**H NMR** (500 MHz, CDCl₃) δ 8.14 (s, 1H), 7.83 (d, J = 8.3 Hz, 2H), 7.62 (s, 1H), 7.48 (d, J = 8.7 Hz, 2H), 7.29 (d, J = 8.1 Hz, 4H), 7.15 (d, J = 8.2 Hz, 2H), 6.93 (d, J = 8.6 Hz, 2H), 3.93 (q, J = 7.1 Hz, 1H), 2.47 (d, J = 7.2 Hz, 2H), 2.39 (s, 3H), 1.86 (dp, J = 13.6, 6.8 Hz, 1H), 1.60 (d, J = 7.1 Hz, 3H), 0.91 (s, 3H), 0.90 (s, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 173.2, 152.3, 146.6, 144.3, 141.0, 136.9, 135.2, 130.8, 129.7, 129.6, 128.4, 127.9, 127.2, 121.8, 45.2, 45.0, 30.2, 22.4, 21.6, 18.4.

HRMS (ESI-TOF) m/z: $[M + H]^+$ Calcd for $C_{27}H_{30}N_2O_4SH$ 479.1999; Found: 479.2011.



4-((2-tosylhydrazono)methyl)phenyl 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoate (25a): Following the general procedure B, it was obtained as a white solid by recrystallization (isolated yield: 70%).

¹**H NMR** (500 MHz, CDCl₃) δ 8.33 (s, 1H), 7.85 (d, J = 8.4 Hz, 2H), 7.66 (s, 1H), 7.52 (d, J = 8.6 Hz, 2H), 7.30 (d, J = 7.9 Hz, 2H), 7.02 – 6.99 (m, 1H), 6.97 (d, J = 8.7 Hz, 2H), 6.67 (d, J = 6.6 Hz, 1H), 6.63 (s, 1H), 3.98 (t, J = 5.4 Hz, 2H), 2.40 (s, 3H), 2.30 (s, 3H), 2.16 (s, 3H), 1.88 (s, 4H), 1.37 (s, 6H). ¹³**C NMR** (126 MHz, CDCl₃) δ 176.4, 156.8, 152.4, 146.6, 144.3, 136.5, 135.2, 130.8, 130.3, 129.7, 128.4, 127.9, 123.5, 121.9, 120.8, 111.9, 67.6, 42.5, 37.0, 25.2, 25.1, 21.6, 21.4, 15.8.

HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₂₉H₃₄N₂O₅SH 535.2261; Found: 535.2283.



2-benzyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (1d)

Prepared according to the general procedure A. Following workup, the product was purified by column chromatography (eluent: petroleum ether/EtOAc = 60/1) to give the title compound as a colorless liquid (isolated yield: 64%). **1d** was known in the published literature.¹⁶

¹**H NMR** (500 MHz, CDCl₃) *δ* 7.27 – 7.22 (m, 2H), 7.20 – 7.18 (m, 2H), 7.15 – 7.10 (m, 1H), 2.30 (s, 2H), 1.24 (s, 12H).

¹³C NMR (126 MHz, CDCl₃) *δ* 138.9, 129.2, 128.5, 125.1, 83.6, 25.0.

HRMS (ESI-TOF) m/z: $[M + H]^+$ Calcd for $C_{13}H_{19}BO_2H$ 219.1551; Found: 219.1568.



4,4,5,5-tetramethyl-2-(4-methylbenzyl)-1,3,2-dioxaborolane (2d)

Prepared according to the general procedure A. Following workup, the product was purified by column chromatography (eluent: petroleum ether/EtOAc = 60/1) to give the title compound as a colorless liquid (isolated yield: 53%). **2d** was known in the published literature.¹⁶

¹**H NMR** (500 MHz, CDCl₃) δ 7.10 – 7.03 (m, 4H), 2.30 (s, 3H), 2.26 (s, 2H), 1.24 (s, 12H).

¹³C NMR (126 MHz, CDCl₃) *δ* 135.5, 134.2, 129.1, 129.0, 83.5, 24.9, 21.1.

HRMS (ESI-TOF) m/z: $[M + H]^+$ Calcd for $C_{14}H_{21}BO_2H$ 233.1707; Found: 233.1721.



2-(4-(tert-butyl)benzyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (3d)

Prepared according to the general procedure A. Following workup, the product was purified by column chromatography (eluent: petroleum ether/EtOAc = 60/1) to give the title compound as a colorless liquid (isolated yield: 63%). **3d** was known in the published literature.¹⁷

¹**H NMR** (400 MHz, CDCl₃) *δ* 7.29 – 7.23 (d, 2H), 7.14 – 7.09 (d, 2H), 2.27 (s, 2H), 1.30 (s, 9H), 1.25 (s, 12H).

¹³C NMR (126 MHz, CDCl₃) *δ* 147.6, 135.5, 128.8, 125.3, 83.5, 34.4, 31.6, 24.9.

HRMS (ESI-TOF) m/z: $[M + H]^+$ Calcd for $C_{17}H_{27}BO_2H$ 275.2177; Found: 275.2190.



2-(4-methoxybenzyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (4d)

Prepared according to the general procedure A. Following workup, the product was purified by column chromatography (eluent: petroleum ether/EtOAc = 50/1) to give the title compound as a colorless liquid (isolated yield: 46%). **4d** was known in the published literature.¹⁶

¹**H NMR** (400 MHz, CDCl₃) δ 7.10 (d, J = 8.7 Hz, 2H), 6.79 (d, J = 8.6 Hz, 2H), 3.77 (s, 3H), 2.23 (s, 2H), 1.23 (s, 12H).

¹³C NMR (101 MHz, CDCl₃) δ 157.2, 130.6, 129.9, 113.9, 83.5, 55.3, 24.9.

HRMS (ESI-TOF) m/z: $[M + H]^+$ Calcd for $C_{14}H_{21}BO_3H$ 249.1657; Found: 249.1666.



4,4,5,5-tetramethyl-2-(4-(methylthio)benzyl)-1,3,2-dioxaborolane (5d)

Prepared according to the general procedure A. Following workup, the product was purified by column chromatography (eluent: petroleum ether/EtOAc = 60/1) to give the title compound as a colorless liquid (isolated yield: 70%). **5d** was known in the published literature.¹⁸

¹**H NMR** (500 MHz, CDCl₃) δ 7.16 (d, J = 8.3 Hz, 2H), 7.11 (d, J = 8.2 Hz, 2H), 2.45 (s, 3H), 2.25 (s, 2H), 1.23 (s, 12H).

¹³C NMR (126 MHz, CDCl₃) *δ* 136.0, 134.1, 129.6, 127.5, 83.6, 24.9, 16.6.

HRMS (ESI-TOF) m/z: $[M + H]^+$ Calcd for C₁₄H₂₁BO₂SH 265.1428; Found: 265.1439.



4,4,5,5-tetramethyl-2-(4-phenoxybenzyl)-1,3,2-dioxaborolane (6d)

Prepared according to the general procedure A. Following workup, the product was purified by column chromatography (eluent: petroleum ether/EtOAc = 60/1) to give the title compound as a colorless liquid (isolated yield: 60%). **6d** was known in the published literature.¹⁸

¹**H NMR** (500 MHz, CDCl₃) δ 7.31 (dd, J = 8.7, 7.4 Hz, 2H), 7.18 – 7.13 (m, 2H), 7.06 (tt, J = 7.4, 1.1 Hz, 1H), 7.00 – 6.96 (m, 2H), 6.91 (d, J = 8.5 Hz, 2H), 2.28 (s, 2H), 1.25 (s, 12H).

¹³C NMR (126 MHz, CDCl₃) δ 157.9, 154.5, 133.7, 130.3, 129.7, 122.8, 119.2, 118.5, 83.6, 24.9. HRMS (ESI-TOF) m/z: $[M + H]^+$ Calcd for C₁₉H₂₃BO₃H 311.1813; Found: 311.1831.



2-([1,1'-biphenyl]-4-ylmethyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (7d)

Prepared according to the general procedure A. Following workup, the product was purified by column chromatography (eluent: petroleum ether/EtOAc = 60/1) to give the title compound as a colorless liquid (isolated yield: 80%). **7d** was known in the published literature.¹⁶

¹**H NMR** (500 MHz, CDCl₃) δ 7.57 – 7.53 (m, 2H), 7.45 (d, J = 8.1 Hz, 2H), 7.38 (t, J = 7.7 Hz, 2H), 7.28 (d, J = 7.3 Hz, 1H), 7.23 (d, J = 8.0 Hz, 2H), 2.31 (s, 2H), 1.22 (s, 12H).

¹³C NMR (126 MHz, CDCl₃) δ 141.4, 138.0, 137.9, 129.5, 128.8, 127.1, 127.0, 127.0, 83.6, 24.9.

HRMS (ESI-TOF) m/z: $[M + H]^+$ Calcd for $C_{19}H_{23}BO_2H$ 295.1864; Found: 295.1877.



2-(4-ethynylbenzyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (8d)

Prepared according to the general procedure A. Following workup, the product was purified by column chromatography (eluent: petroleum ether/EtOAc = 60/1) to give the title compound as a colorless liquid (isolated yield: 53%).

¹**H NMR** (500 MHz, CDCl₃) δ 7.37 (d, J = 8.2 Hz, 2H), 7.16 – 7.07 (m, 2H), 3.01 (s, 1H), 2.29 (s, 2H), 1.22 (s, 12H).

¹³C NMR (126 MHz, CDCl₃) δ 140.1, 132.2, 129.1, 118.6, 84.2, 83.7, 76.4, 24.8.

HRMS (ESI-TOF) m/z: $[M + H]^+$ Calcd for $C_{15}H_{19}BO_2H$ 243.1551; Found: 243.1567.



4,4,5,5-tetramethyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-1,3,2-dioxaborolane (9d)

Prepared according to the general procedure A. Following workup, the product was purified by column chromatography (eluent: petroleum ether/EtOAc = 30/1) to give the title compound as a colorless liquid (isolated yield: 42%). **9d** was known in the published literature.¹⁶

¹**H NMR** (500 MHz, CDCl₃) δ 7.69 (d, J = 7.9 Hz, 2H), 7.19 (d, J = 7.9 Hz, 2H), 2.30 (s, 2H), 1.33 (s, 12H), 1.21 (s, 12H).

¹³C NMR (126 MHz, CDCl₃) δ 142.5, 135.0, 128.6, 83.7, 83.6, 25.0, 24.8.

HRMS (ESI-TOF) m/z: $[M + H]^+$ Calcd for $C_{19}H_{30}B_2O_4H$ 345.2403; Found: 345.2422.



4,4,5,5-tetramethyl-2-(4-(trifluoromethoxy)benzyl)-1,3,2-dioxaborolane (10d)

Prepared according to the general procedure A. Following workup, the product was purified by column chromatography (eluent: petroleum ether/EtOAc = 60/1) to give the title compound as a colorless liquid (isolated yield: 50%). **10d** was known in the published literature.¹⁹

¹**H NMR** (500 MHz, CDCl₃) δ 7.22 – 7.15 (m, 2H), 7.11 – 7.00 (m, 2H), 2.29 (s, 2H), 1.24 (s, 12H). ¹³**C NMR** (126 MHz, CDCl₃) δ 146.9, 137.6, 130.2, 123.5, 121.7(q, J_{C-F} = 257.04 Hz), 83.7, 24.9.

¹⁹**F NMR** (376 MHz, CDCl₃) δ -57.93.

HRMS (ESI-TOF) m/z: $[M + H]^+$ Calcd for $C_{14}H_{18}BF_3O_3H$ 303.1374; Found: 303.1399.



2-(4-fluorobenzyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (11d)

Prepared according to the general procedure A. Following workup, the product was purified by column chromatography (eluent: petroleum ether/EtOAc = 60/1) to give the title compound as a colorless liquid (isolated yield: 55%). **11d** was known in the published literature.¹⁶

¹**H NMR** (500 MHz, CDCl₃) *δ*7.16 – 7.07 (m, 2H), 6.96 – 6.83 (m, 2H), 2.25 (s, 2H), 1.23 (s, 12H).

¹³C NMR (126 MHz, CDCl₃) δ 161.9, 160.0, 134.2 (d, $J_{C-F} = 2.5$ Hz), 130.3 (d, $J_{C-F} = 7.6$ Hz), 115.1 (d, $J_{C-F} = 21.4$ Hz), 83.6, 24.9.

¹⁹**F NMR** (376 MHz, CDCl₃) *δ* -119.37.

HRMS (ESI-TOF) m/z: $[M + H]^+$ Calcd for $C_{13}H_{18}BFO_2H$ 237.1457; Found: 237.1477.



2-(4-chlorobenzyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (12d)

Prepared according to the general procedure A. Following workup, the product was purified by column chromatography (eluent: petroleum ether/EtOAc = 60/1) to give the title compound as a colorless liquid (isolated yield: 75%). **12d** was known in the published literature.¹⁶

¹**H NMR** (500 MHz, CDCl₃) δ 7.19 (d, J = 8.4 Hz, 2H), 7.10 (d, J = 8.4 Hz, 2H), 2.25 (s, 2H), 1.23 (s, 12H).

¹³C NMR (126 MHz, CDCl₃) *δ* 137.3, 130.7, 130.4, 128.4, 83.7, 24.8.

HRMS (ESI-TOF) m/z: $[M + H]^+$ Calcd for $C_{13}H_{18}BClO_2H$ 253.1161; Found: 253.1189.



2-(4-bromobenzyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (13d)

Prepared according to the general procedure A. Following workup, the product was purified by column chromatography (eluent: petroleum ether/EtOAc = 60/1) to give the title compound as a colorless liquid (isolated yield: 82%). **13d** was known in the published literature.¹⁶

¹**H NMR** (500 MHz, CDCl₃) δ 7.34 (d, J = 8.3 Hz, 2H), 7.05 (d, J = 8.3 Hz, 2H), 2.23 (s, 2H), 1.23 (s, 12H).

¹³C NMR (126 MHz, CDCl₃) δ 137.8, 131.4, 130.9, 118.7, 83.7, 24.8.

HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₁₃H₁₈BBrO₂H 297.0656; Found: 297.0677.



2-(3-fluorobenzyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (14d)

Prepared according to the general procedure A. Following workup, the product was purified by column chromatography (eluent: petroleum ether/EtOAc = 60/1) to give the title compound as a colorless liquid (isolated yield: 65%). **14d** was known in the published literature.¹⁹

¹**H NMR** (500 MHz, CDCl₃) δ 7.18 (td, J = 7.9, 6.2 Hz, 1H), 6.97 – 6.92 (m, 1H), 6.90 (dt, J = 10.3, 2.1 Hz, 1H), 6.85 – 6.78 (m, 1H), 2.29 (s, 2H), 1.23 (s, 12H).

¹³C NMR (126 MHz, CDCl₃) δ 163.0 (d, $J_{C-F} = 245.7$ Hz), 141.4 (d, $J_{C-F} = 7.6$ Hz), 129.6 (d, $J_{C-F} = 8.8$ Hz), 124.8 (d, $J_{C-F} = 2.5$ Hz), 116.0 (d, $J_{C-F} = 21.4$ Hz), 111.9 (d, $J_{C-F} = 21.4$ Hz), 83.7, 24.9. ¹⁹F NMR (376 MHz, CDCl₃) δ -114.28.

HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₁₃H₁₈BFO₂H 237.1457; Found: 237.1485.



2-(3-bromobenzyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (15d)

Prepared according to the general procedure A. Following workup, the product was purified by column chromatography (eluent: petroleum ether/EtOAc = 60/1) to give the title compound as a colorless liquid (isolated yield: 68%). **15d** was known in the published literature.¹⁶

¹**H NMR** (500 MHz, CDCl₃) δ 7.33 (dq, J = 1.3, 0.8 Hz, 1H), 7.26 – 7.24 (m, 1H), 7.10 (d, J = 1.0 Hz, 1H), 7.09 (dd, J = 2.2, 1.0 Hz, 1H), 2.26 (s, 2H), 1.23 (s, 12H).

¹³C NMR (126 MHz, CDCl₃) δ 141.2, 132.1, 129.9, 128.1, 127.8, 122.4, 83.8, 24.9.

HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₁₃H₁₈BBrO₂H 297.0656; Found: 297.0684.



4,4,5,5-tetramethyl-2-(3-(trifluoromethyl)benzyl)-1,3,2-dioxaborolane (16d)

Prepared according to the general procedure A. Following workup, the product was purified by column chromatography (eluent: petroleum ether/EtOAc = 60/1) to give the title compound as a colorless liquid (isolated yield: 75%). **16d** was known in the published literature.²⁰

¹**H NMR** (500 MHz, CDCl₃) δ 7.44 (dt, J = 1.8, 0.9 Hz, 1H), 7.39 – 7.32 (m, 3H), 2.35 (s, 2H), 1.24 (s, 12H).

¹³**C NMR** (126 MHz, CDCl₃) δ 139.7, 132.4, 130.4 (q, J_{C-F} = 31.9 Hz), 128.6, 125.7 (d, J_{C-F} = 3.8 Hz), 124.4 (q, J_{C-F} = 272.9 Hz), 121.8 (d, J_{C-F} = 3.7 Hz), 83.7, 24.7

¹⁹**F NMR** (376 MHz, CDCl₃) δ -62.61.

HRMS (ESI-TOF) m/z: $[M + H]^+$ Calcd for $C_{14}H_{18}BF_3O_2H$ 287.1425; Found: 287.1459.



4,4,5,5-tetramethyl-2-(naphthalen-2-ylmethyl)-1,3,2-dioxaborolane (17d)

Prepared according to the general procedure A. Following workup, the product was purified by column chromatography (eluent: petroleum ether/EtOAc = 20/1) to give the title compound as a white solid (isolated yield: 65%). **17d** was known in the published literature.¹⁶

¹**H NMR** (500 MHz, CDCl₃) δ 7.82 – 7.71 (m, 3H), 7.65 – 7.61 (m, 1H), 7.41 (m, 2H), 7.35 (dd, *J* = 8.4, 1.8 Hz, 1H), 2.47 (s, 2H), 1.24 (s, 12H).

¹³**C NMR** (126 MHz, CDCl₃) *δ* 136.4, 133.9, 131.6, 128.4, 127.8, 127.7, 127.4, 126.7, 125.8, 124.8, 83.6, 24.9.

HRMS (ESI-TOF) m/z: $[M + H]^+$ Calcd for $C_{17}H_{21}BO_2H$ 269.1707; Found: 269.1745.



2-(2-bromo-4-methoxybenzyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (18d)

Prepared according to the general procedure A. Following workup, the product was purified by column chromatography (eluent: petroleum ether/EtOAc = 30/1) to give the title compound as a colorless crystal (isolated yield: 48%).

¹**H NMR** (500 MHz, CDCl₃) δ 7.13 (d, J = 8.5 Hz, 1H), 7.07 (d, J = 2.7 Hz, 1H), 6.76 (dd, J = 8.4, 2.7 Hz, 1H), 3.76 (s, 3H), 2.33 (s, 2H), 1.25 (s, 12H).

¹³**C NMR** (126 MHz, CDCl₃) δ 157.8, 131.3, 131.0, 124.7, 117.7, 113.7, 83.7, 55.6, 24.9. **HRMS** (ESI-TOF) m/z: [M + H]⁺ Calcd for C₁₄H₂₀BBrO₃H 327.0762, Found: 327,0799.



2-(3,5-dichlorobenzyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (19d)

Prepared according to the general procedure A. Following workup, the product was purified by column chromatography (eluent: petroleum ether/EtOAc = 60/1) to give the title compound as a colorless liquid (isolated yield: 65%).

¹**H NMR** (500 MHz, CDCl₃) δ 7.12 (t, J = 1.9 Hz, 1H), 7.06 (t, J = 1.3 Hz, 2H), 2.24 (s, 2H), 1.24 (s, 12H).

¹³C NMR (126 MHz, CDCl₃) *δ* 142.3, 134.6, 127.6, 125.3, 83.9, 24.9.

HRMS (ESI-TOF) m/z: $[M + H]^+$ Calcd for $C_{13}H_{17}BCl_2O_2H$ 287.0771, Found: 287.0799.



4,4,5,5-tetramethyl-2-(2,4,6-trifluorobenzyl)-1,3,2-dioxaborolane (20d)

Prepared according to the general procedure A. Following workup, the product was purified by column chromatography (eluent: petroleum ether/EtOAc = 60/1) to give the title compound as a colorless liquid (isolated yield: 55%).

¹**H NMR** (500 MHz, CDCl₃) δ 6.60 (dd, J = 8.9, 7.4 Hz, 2H), 2.16 (s, 2H), 1.24 (s, 12H).

¹³C NMR (126 MHz, CDCl₃) δ 162.16 (q, $J_{C-F} = 2.5$ Hz), 161.3, 160.2 (q, $J_{C-F} = 2.5$ Hz), 159.4, 111.1 (td, $J_{C-F} = 21.4$ Hz, 3.8 Hz), 99.8 (q, $J_{C-F} = 25.2$ Hz, 7.6 Hz), 83.9, 24.8.

HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₁₃H₁₆BF₃O₂H 273.1268, Found: 273.1303.



2-((4-bromothiophen-3-yl)methyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (21d)

Prepared according to the general procedure A. Following workup, the product was purified by column chromatography (eluent: petroleum ether/EtOAc = 60/1) to give the title compound as a colorless liquid (isolated yield: 80%).

¹**H NMR** (500 MHz, CDCl₃) δ 7.20 (d, *J* = 3.4 Hz, 1H), 7.05 (dt, *J* = 3.4, 1.0 Hz, 1H), 2.25 (s, 2H), 1.27 (s, 12H).

¹³C NMR (126 MHz, CDCl₃) δ 137.7, 122.4, 120.8, 113.8, 83.8, 25.0.

HRMS (ESI-TOF) m/z: $[M + H]^+$ Calcd for $C_{11}H_{16}BBrO_2SH$ 303.0220, Found: 303.0255.



1,3-bis((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)benzene (22d)

Prepared according to the general procedure A. Following workup, the product was purified by column chromatography (eluent: petroleum ether/EtOAc = 40/1) to give the title compound as a colorless liquid (isolated yield: 65%). **22d** was known in the published literature.²¹

¹**H NMR** (500 MHz, CDCl₃) δ 7.10 (t, J = 7.6 Hz, 1H), 6.97 (d, J = 1.8 Hz, 1H), 6.93 (dd, J = 7.6, 1.7 Hz, 2H), 2.23 (s, 4H), 1.22 (s, 24H).

¹³C NMR (126 MHz, CDCl₃) δ 138.5, 129.9, 128.3, 125.7, 83.5, 24.8.

HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₂₀H₃₂B₂O₄H 359.2559, Found: 359.2587.



1,4-bis((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)benzene (23d)

Prepared according to the general procedure A. Following workup, the product was purified by column chromatography (eluent: petroleum ether/EtOAc = 40/1) to give the title compound as a colorless liquid (isolated yield: 72%). **23d** was known in the published literature.²¹

¹**H NMR** (400 MHz, CDCl₃) *δ* 7.04 (s, 4H), 2.23 (s, 4H), 1.22 (s, 24H).

¹³C NMR (101 MHz, CDCl₃) δ 134.8, 129.1, 83.5, 24.8.

HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₂₀H₃₂B₂O₄H 359.2559, Found: 359.2592.



4-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)phenyl-2-(4-isobutylphenyl)propanoate (24d)

Prepared according to the general procedure A. Following workup, the product was purified by column chromatography (eluent: petroleum ether/EtOAc = 30/1) to give the title compound as a yellow solid (isolated yield: 40%).

¹**H** NMR (500 MHz, CDCl₃) δ 7.30 (d, J = 7.8 Hz, 2H), 7.13 (d, J = 8.0 Hz, 4H), 6.86 (d, J = 8.5 Hz, 2H), 3.92 (q, J = 7.1 Hz, 1H), 2.47 (d, J = 7.1 Hz, 2H), 2.26 (s, 2H), 1.87 (m, 1H), 1.59 (d, J = 7.1 Hz, 3H), 1.22 (d, J = 0.9 Hz, 12H), 0.91 (d, J = 6.6 Hz, 6H).

¹³C NMR (126 MHz, CDCl₃) *δ* 173.5, 148.4, 140.8, 137.5, 136.2, 129.8, 129.6, 129.6, 127.3, 121.1, 83.6, 45.4, 45.2, 30.3, 24.8, 22.5, 18.7.

HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₂₆H₃₅BO₄H 423.2701, Found: 423.2738.



4-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)phenyl-5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoate (25d)

Prepared according to the general procedure A. Following workup, the product was purified by column chromatography (eluent: petroleum ether/EtOAc = 30/1) to give the title compound as a yellow solid (isolated yield: 63%).

¹**H NMR** (500 MHz, CDCl₃) δ 7.18 (d, J = 8.5 Hz, 2H), 7.05 – 6.98 (m, 1H), 6.91 (d, J = 8.4 Hz, 2H), 6.69 – 6.66 (m, 1H), 6.64 (d, J = 1.6 Hz, 1H), 3.99 (m, 2H), 2.32 (s, 3H), 2.29 (s, 2H), 2.19 (s, 3H), 1.88 (m, 4H), 1.37 (s, 6H), 1.24 (s, 12H).

¹³C NMR (126 MHz, CDCl₃) *δ* 176.7, 157.0, 148.5, 136.6, 136.1, 130.4, 129.9, 128.1, 123.7, 121.7, 121.3, 120.8, 112.1, 83.6, 67.9, 42.5, 37.3, 25.4, 25.3, 24.9, 21.5, 15.9.

HRMS (ESI-TOF) m/z: $[M + H]^+$ Calcd for $C_{28}H_{39}BO_5H$ 467.2963, Found: 467.2999.



4-((hydroxyimino)methyl)phenyl 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoate (25e)

Prepared according to the general procedure D. Following workup, the product was purified by column chromatography (eluent: petroleum ether/EtOAc = 10/1) to give the title compound as a yellow solid (isolated yield: 85%).

¹**H NMR** (500 MHz, CDCl₃) δ 8.13 (s, 1H), 8.00 (s, 1H), 7.58 (d, J = 8.6 Hz, 2H), 7.06 (d, J = 8.7 Hz, 2H), 7.01 (d, J = 7.4 Hz, 1H), 6.67 (dd, J = 7.5, 1.5 Hz, 1H), 6.63 (d, J = 1.5 Hz, 1H), 3.99 (t, J = 5.3 Hz, 2H), 2.31 (s, 3H), 2.18 (s, 3H), 1.92 – 1.78 (m, 4H), 1.38 (s, 6H).

¹³C NMR (126 MHz, CDCl₃) *δ* 176.3, 156.9, 152.4, 149.6, 136.6, 130.5, 129.7, 128.2, 123.7, 122.2, 120.9, 112.1, 67.8, 42.7, 37.3, 25.4, 25.3, 21.6, 15.9.

HRMS (EI-TOF) m/z: [M]⁺ Calcd for C₂₂H₂₇NO₄H 370.2013; Found 370.2045.



$\label{eq:constraint} 4-(((3aS)-3a,5,5-trimethyl hexahydro-4,6-methanobenzo[d][1,3,2] dioxaborol-2-yl) methyl) phenyl and the statemethyl hexahydro-4,6-methanobenzo[d][1,3,2] dioxaborol-2-yl) methyl hexahydro-4,6-methanobenzo[d][1,3,2] dioxaborol-2-yl) methyl hexahydro-4,6-methanobenzo[d][1,3,2] dioxaborol-2-yl) methyl hexahydro-4,6-methanobenzo[d][1,3,2] dioxaborol-2-yl] methyl hexahydro-4,0-methanobenzo[d][$

5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoate (25f)

Prepared according to the general procedure E. Following workup, the product was purified by column chromatography (eluent: petroleum ether/EtOAc = 30/1) to give the title compound as a yellow solid (isolated yield: 88%).

¹**H NMR** (500 MHz, CDCl₃) δ 7.22 – 7.16 (m, 2H), 7.04 – 6.99 (m, 1H), 6.96 – 6.85 (m, 2H), 6.67 (dd, J = 7.2, 1.4 Hz, 1H), 6.64 (d, J = 1.5 Hz, 1H), 4.28 (dd, J = 8.7, 2.0 Hz, 1H), 3.98 (m, 2H), 2.32 (d, J = 8.6 Hz, 2H), 2.29 (t, J = 2.4 Hz, 4H), 2.19 (s, 4H), 2.05 (dd, J = 6.0, 5.1 Hz, 1H), 1.92 – 1.87 (m, 6H), 1.39 (s, 3H), 1.36 (s, 6H), 1.28 (s, 3H), 1.05 (d, J = 10.9 Hz, 1H), 0.83 (s, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 176.6, 157.0, 148.5, 136.6, 136.2, 130.4, 129.9, 123.7, 121.3, 120.8, 112.0, 86.0, 78.1, 77.4, 67.9, 51.4, 51.0, 42.5, 39.7, 39.5, 38.2, 38.0, 37.3, 35.5, 35.1, 28.7, 27.2, 26.7, 26.5, 25.4, 25.3, 24.1, 21.5, 15.9.

HRMS (EI-TOF) m/z: [M]⁺ Calcd for C₃₂H₄₃BO₅H 519.3276; Found 519.3287.



4-((methyl(phenyl)amino)methyl)phenyl 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoate (25g)

Prepared according to the general procedure F. Following workup, the product was purified by column chromatography (eluent: petroleum ether/EtOAc = 30/1) to give the title compound as a yellow solid (isolated yield: 63%).

¹**H NMR** (500 MHz, CDCl₃) δ 7.23 (dt, J = 8.8, 3.8 Hz, 4H), 7.01 (d, J = 7.5 Hz, 1H), 6.98 (d, J = 8.5 Hz, 2H), 6.76 (dd, J = 8.8, 1.1 Hz, 2H), 6.74 – 6.71 (m, 1H), 6.67 (dd, J = 7.6, 1.5 Hz, 1H), 6.63 (d, J = 1.5 Hz, 1H), 4.52 (s, 2H), 3.98 (q, J = 3.2 Hz, 2H), 3.01 (s, 3H), 2.31 (s, 3H), 2.18 (s, 3H), 1.88 (d, J = 2.9 Hz, 4H), 1.37 (s, 6H).

¹³C NMR (126 MHz, CDCl₃) δ 176.6, 157.0, 150.0, 149.8, 136.6, 136.5, 130.5, 129.3, 127.8, 123.7, 121.7, 120.9, 116.8, 112.6, 112.1, 67.9, 56.3, 42.6, 38.6, 37.3, 25.4, 25.3, 21.6, 16.0.

HRMS (EI-TOF) m/z: [M]⁺ Calcd for C₂₉H₃₅NO₃H 446.2690; Found 446.2723.



4-((4-bromophenoxy)methyl)phenyl 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoate (25h)

Prepared according to the general procedure G. Following workup, the product was purified by column chromatography (eluent: petroleum ether/EtOAc = 10/1) to give the title compound as a yellow solid (isolated yield: 50%).

¹**H NMR** (500 MHz, CDCl₃) δ 7.39 (dd, J = 15.1, 8.8 Hz, 4H), 7.11 – 7.03 (m, 2H), 7.00 (d, J = 7.5 Hz, 1H), 6.88 – 6.79 (m, 2H), 6.67 (d, J = 7.4 Hz, 1H), 6.65 – 6.61 (m, 1H), 5.02 (s, 2H), 4.00 – 3.92 (m, 2H), 2.30 (s, 3H), 2.17 (s, 3H), 1.88 (dd, J = 3.2, 1.7 Hz, 4H), 1.37 (s, 6H).

¹³C NMR (126 MHz, CDCl₃) *δ* 176.5, 157.8, 157.0, 150.9, 136.6, 134.1, 132.5, 130.5, 128.6, 123.7, 121.9, 120.9, 116.8, 113.4, 112.1, 69.8, 67.9, 42.6, 37.3, 25.4, 25.3, 21.6, 16.0.

HRMS (EI-TOF) m/z: [M]⁺ Calcd for C₂₈H₃₁BrO₄H 511.1478, Found 511.1507.

8 NMR spectra of products and synthesized substrates



¹H NMR (500 MHz, CDCl₃) spectra for 1a





¹H NMR (500 MHz, DMSO-d₆) spectra for 3a



¹H NMR (500 MHz, DMSO-d₆) spectra for 5a



¹H NMR (500 MHz, DMSO-d₆) spectra for 6a


¹H NMR (500 MHz, DMSO-d₆) spectra for 7a



¹H NMR (500 MHz, DMSO-d₆) spectra for 8a



¹³C NMR (126 MHz, DMSO-d₆) spectra for 8a



¹H NMR (500 MHz, DMSO-d₆) spectra for 9a



¹³C NMR (126 MHz, DMSO-d₆) spectra for 9a



¹H NMR (500 MHz, CDCl₃) spectra for 11a



¹H NMR (500 MHz, DMSO-d₆) spectra for 12a



¹H NMR (500 MHz, DMSO-d₆) spectra for 14a



12.0 11.5 11.0 10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0. fl (ppm)

¹H NMR (500 MHz, DMSO-d₆) spectra for 15a



¹³C NMR (126 MHz, DMSO-d₆) spectra for 15a



¹H NMR (500 MHz, DMSO-d₆) spectra for 17a



¹³C NMR (126 MHz, DMSO-*d*₆) spectra for 18a.



¹³C NMR (126 MHz, DMSO-d₆) spectra for 19a



¹H NMR (500 MHz, DMSO-d₆) spectra for 20a







220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 fl (ppm)









S49

12.0 11.5 11.0 10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 fl (ppm)

2.04_₹ 3.09 1.03₄ 3.18_{*} 3.023.18

 1.04_{II}

 $\begin{array}{c} 0.97\\ 2.00\\ 1.00\\ 4.09\\ 2.01\\ 1.00\\$





S50

¹³C NMR (126 MHz, CDCl₃) spectra for 25a





¹H NMR (500 MHz, CDCl₃) and ¹³C NMR (126 MHz, CDCl₃) spectra for 1d

210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 fl (ppm)



¹H NMR (500 MHz, CDCl₃) and ¹³C NMR (126 MHz, CDCl₃) spectra for 2d



¹H NMR (500 MHz, CDCl₃) and ¹³C NMR (126 MHz, CDCl₃) spectra for 3d



¹H NMR (500 MHz, CDCl₃) and ¹³C NMR (126 MHz, CDCl₃) spectra for 4d

240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 fl (ppm) $^{-10}$



¹H NMR (500 MHz, CDCl₃) and ¹³C NMR (126 MHz, CDCl₃) spectra for 5d



¹H NMR (500 MHz, CDCl₃) and ¹³C NMR (126 MHz, CDCl₃) spectra for 6d



¹H NMR (500 MHz, CDCl₃) and ¹³C NMR (126 MHz, CDCl₃) spectra for 7d



¹H NMR (500 MHz, CDCl₃) and ¹³C NMR (126 MHz, CDCl₃) spectra for 8d







¹H NMR (500 MHz, CDCl₃) and ¹³C NMR (126 MHz, CDCl₃) spectra for 10d

¹⁹F NMR (376 MHz, CDCl₃)



20 10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 -2 fl (ppm)



¹H NMR (500 MHz, CDCl₃) and ¹³C NMR (126 MHz, CDCl₃) spectra for 11d

fl (ppm)



 1H NMR (500 MHz, CDCl₃) and ^{13}C NMR (126 MHz, CDCl₃) spectra for 12d





¹H NMR (500 MHz, CDCl₃) and ¹³C NMR (126 MHz, CDCl₃) spectra for 13d



¹H NMR (500 MHz, CDCl₃) and ¹³C NMR (126 MHz, CDCl₃) spectra for 14d



20 10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 -2. fl (ppm)



¹H NMR (500 MHz, CDCl₃) and ¹³C NMR (126 MHz, CDCl₃) spectra for 15d

fl (ppm)



¹H NMR (500 MHz, CDCl₃) and ¹³C NMR (126 MHz, CDCl₃) spectra for 16d

¹⁹F NMR (376 MHz, CDCl₃)



20 10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 -2 fl (ppm)



¹H NMR (500 MHz, CDCl₃) and ¹³C NMR (126 MHz, CDCl₃) spectra for 17d



^1H NMR (500 MHz, CDCl₃) and ^{13}C NMR (126 MHz, CDCl₃) spectra for 18d


 1H NMR (500 MHz, CDCl₃) and ^{13}C NMR (126 MHz, CDCl₃) spectra for 19d



¹H NMR (500 MHz, CDCl₃) and ¹³C NMR (126 MHz, CDCl₃) spectra for 20d



¹H NMR (500 MHz, CDCl₃) and ¹³C NMR (126 MHz, CDCl₃) spectra for 21d



1H NMR (500 MHz, CDCl₃) and ^{13}C NMR (126 MHz, CDCl₃) spectra for 22d



 ^1H NMR (500 MHz, CDCl₃) and ^{13}C NMR (126 MHz, CDCl₃) spectra for 23d

fl (ppm)



¹H NMR (500 MHz, CDCl₃) and ¹³C NMR (126 MHz, CDCl₃) spectra for 24d



¹H NMR (500 MHz, CDCl₃) and ¹³C NMR (126 MHz, CDCl₃) spectra for 25d



¹H NMR (500 MHz, CDCl₃) and ¹³C NMR (126 MHz, CDCl₃) spectra for 25e



¹H NMR (500 MHz, CDCl₃) and ¹³C NMR (126 MHz, CDCl₃) spectra for 25f



1H NMR (500 MHz, CDCl_3) and ^{13}C NMR (126 MHz, CDCl_3) spectra for 25g



¹H NMR (500 MHz, CDCl₃) and ¹³C NMR (126 MHz, CDCl₃) spectra for 25h

9. References

- Zhang, B. H., Lei, L. S., Liu, S. Z., Mou, X. Q., Liu, W. T., Wang, S. H., Wang, J., Bao, W., Zhang, K. Zinc-promoted cyclization of tosylhydrazones and 2-(dimethylamino) malononitrile: an efficient strategy for the synthesis of substituted 1-tosyl-1*H*-pyrazoles. *Chem. Commun.* 2017, *53*, 8545-8548.
- 2. B. Neises., Steglich. W., Chem. Inform. 2016, 9.
- Wang, Z., Wierich, N., Zhang, J., Daniliuc, C. G., Studer, A. Alkyl Radical Generation from Alkylboronic Pinacol Esters through Substitution with Aminyl Radicals. *J. Am. Chem. Soc.* 2023, *145*, 8770-8775.
- 4. Xie, Q., Dong, G. Programmable ether synthesis enabled by oxa-Matteson reaction. *J. Am. Chem. Soc.* **2022**, *144*, 8498-8503.
- 5. Sueki, S., Kuninobu, Y. Copper-catalyzed *N*-and *O*-alkylation of amines and phenols using alkylborane reagents. *Org. Lett.* **2013**, *15*, 1544-1547.
- 6. Bamford, W. R., Stevens, T. S., The decomposition of toluene-p-sulphonylhydrazones by alkali. J. Chem. Soc. **1952**, 4735-4740.
- 7. Zhou, L., Ye, F., Zhang, Y., Pd-catalyzed three-component coupling of *N*-tosylhydrazone, terminal alkyne, and aryl halide. *J. Am. Chem. Soc.* **2010**, *132*, 13590-13591.
- Zhao, G., Wu, Y., Wu, H. H., Yang, J., Zhang, J., Pd/GF-Phos-catalyzed asymmetric threecomponent C(sp³)–C(sp³) bond formation to access chiral diarylmethyl alkynes. *J. Am. Chem. Soc.* 2021, *143*, 17983-8.
- 9. Arunprasath, D., Muthupandi, P., Sekar, G., Palladium-catalyzed intermolecular carbene insertion prior to intramolecular heck cyclization: Synthesis of 2-arylidene-3-aryl-1-indanones. *Org. Lett.* **2015**, *17*, 5448-5451.
- Han, Y., Yuan, Y., Qi, S., Zhang, Z. K., Kong, X., Yang, J., Zhang, J. Copper-catalyzed sulfur alkylation of sulfenamides with *N*-sulfonylhydrazones. *Org. Lett.* **2024**, *26*, 3906-3910.
- 11. Hossain, M. L., Ye, F., Zhang, Y., CuI-catalyzed cross-coupling of *N*-tosylhydrazones with terminal alkynes: synthesis of 1, 3-disubstituted allenes. *J. Org. Chem.* **2013**, *78*, 1236-1241.
- Barluenga, J., Tomás-Gamasa, M., Aznar, F., Metal-free carbon–carbon bond-forming reductive coupling between boronic acids and tosylhydrazones. *Nat. Chem.* 2009, *1*, 494-499.
- Liao, L. L., Wang, Z. H., Cao, K. G., Sun, G. Q., Zhang, W., Ran, C. K., Yu, D. G. Electrochemical ring-opening dicarboxylation of strained carbon–carbon single bonds with CO₂: facile synthesis of diacids and derivatization into polyesters. *J. Am. Chem. Soc.* 2022, 144, 2062-2068.
- 14. Li, Q., Wang, D., Wang, J., Zhang, L., Xu, X., Han, X., Zhang, W. D. Catalyst-free photoinduced C (sp³)-C (sp³) bond formation through CH insertions using non-activated alkanes/ethers. *Sci. China. Chem.* **2024**, 10.1007/s11426-024-2380-4.
- 15. Yao, X. Q., Wang, Y. S., Wang, J. Palladium-catalyzed carbene coupling polymerization: synthesis of E-poly(arylene vinylene)s. *Chem. Commun.* **2022**, *58*, 4032-4035.
- 16. Li, H., Wang, L., Zhang, Y., Wang, J. Transition-metal-free synthesis of pinacol alkylboronates from tosylhydrazones. *Angew. Chem. Int. Edit.* **2012**, *12*, 2943-2946.

- 17. Pintaric, C., Olivero, S., Gimbert, Y., Chavant, P. Y., Duñach, E. An opportunity for Mgcatalyzed grignard-type reactions: direct coupling of benzylic halides with pinacolborane with 10 mol% of magnesium. *J. Am. Chem. Soc.* **2010**, *132*, 11825-11827.
- 18. Guan, W. Y., Chang, Y. J., Lin, S. Electrochemically Driven Deoxygenative Borylation of Alcohols and Carbonyl Compounds. *J. Am. Chem. Soc.* **2023**, *145*, 16966-16972.
- Bastick, K. A., Watson, A. J. Pd-Catalyzed Organometallic-Free Homologation of Arylboronic Acids Enabled by Chemoselective Transmetalation. ACS. Catal. 2023, 13, 7013-7018.
- Wu, C. Q., Wu, G. J., Zhang, Y., Wang, J. B. One-carbon homologation of arylboronic acids: a convenient approach to the synthesis of pinacol benzylboronates. *Org. Chem. Front.* 2016, *3*, 817-822.
- Palmer, W. N., Obligacion, J. V., Pappas, I., Chirik, P. J. Cobalt-catalyzed benzylic borylation: enabling polyborylation and functionalization of remote, unactivated C (sp3)– H bonds. J. Am. Chem. Soc. 2016, 138, 766-769.